CRISPR Therapeutics AG
CRISPR Therapeutics AG（CRSP）股价预测与分析师目标价
华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。
crsp · 股价预测 · 38 位分析师（近3月）· FMP · 更新于 2026年6月8日
分析师评级与共识
基于过去 3 个月内 38 位华尔街分析师
Buy
38 位分析师
共识
评级分布
12 个月目标价
High
$82.00
Consensus
$64.60
+24.6% upside
Low
$33.00
Median: $76 · Last Close: $51.84
12 个月目标价预测
历史收盘价 + 分析师 12 个月目标价预测区间
Consensus Target
$64.60
24.6% upside
High Target
$82
58.2%
Low Target
$33
-36.3%
Current Price
$51.84
as of today
Based on analyst price targets, the CRSP stock price prediction for the next 12 months ranges from $33 to $82. The consensus CRSP price forecast of $64.60 implies 24.6% upside from the current price of $51.84.
短期股价预测
算法生成 · 每日更新
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $52.68 | ↑ 1.61% |
1-day model range: $52.3–$53.05. Peak: $53.05 (+1.61%).
长期股价预测
年度股价预测 · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $36 | -30.6% |
| 2028 | $29 | -43.4% |
| 2029 | $26 | -49.6% |
| 2030 | $24 | -52.9% |
| 2031 | — | -54.8% |
基于技术分析的股价预测
14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · CRSP · Jun 8, 2026
最新分析师评级与调整
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-13 | Bernstein | Maintains | Market Perform→Market Perform |
| 2026-05-06 | Citigroup | Maintains | Buy→Buy |
| 2026-03-17 | Piper Sandler | Maintains | Overweight→Overweight |
| 2026-02-17 | Chardan Capital | Maintains | Buy→Buy |
| 2026-02-13 | TD Cowen | Maintains | Hold→Hold |
| 2026-02-13 | Evercore ISI Group | Maintains | Outperform→Outperform |
| 2026-02-13 | Needham | Maintains | Buy→Buy |
| 2026-01-30 | Citizens | Maintains | Market Outperform→Market Outperform |
| 2025-12-23 | Citizens | Maintains | Market Outperform→Market Outperform |
| 2025-12-23 | Needham | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on CRISPR Therapeutics AG (CRSP) stock. Of the recent 225 rating actions, 7 were upgrades and 9 were downgrades. 38 analysts currently cover CRSP.
分析师推荐趋势
CRSP analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 3 to 1 per month.
财务预测：EPS 与营收一致预期
Revenue This Year
$40M
↓ 93.2% YoY
Revenue Next Year
$138M
↑ 247.8% YoY
EPS This Year
$-4.87
EPS Next Year
$-3.62
↓ 25.8% YoY
EPS ForecastReported vs Estimated
Analysts forecast CRSP EPS of $-4.87 for the current fiscal year, based on estimates from 17 analysts. The CRSP revenue forecast is $40M for the current year. These are analyst consensus estimates via FMP / S&P Global.
关于预测与目标价
CRSP 股价预测由两类独立数据源支撑：来自 38 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。CRSP 的共识目标价为 $64.60（+24.6% 上行空间），分析师共识为 Buy。
CRSP 的短期预测（明日）为 $52.68（+1.61%）。 CRSP 对 2027 年的股价预测均值为 $36。 CRSP 对 2030 年的预测区间为 $23–$26。
CRISPR Therapeutics AG 在 NASDAQ 上市，代码 CRSP。CRSP 在 2027 年的整体展望偏积极，在覆盖分析师中约 58% 对应 Buy 共识。
常见问题
CRSP 预测 · 8 个问题根据 38 位华尔街分析师，CRSP 的 12 个月平均目标价为 $64.60，最高 $82.00、最低 $33.00。若有图表，中位目标价可在上方查看。相对当前价 $51.84，隐含约 +24.6% 的上行空间。
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.